耐碳青霉烯的高毒力肺炎克雷伯菌(CR-hvKP)的出现促使我们探索抗生素限制的替代疗法。裂解噬菌体被认为是CR-hvKP感染的有希望的替代疗法。在这项研究中,我们报道了三种新的裂解噬菌体,vB_KpnA_SCNJ1-Z,vB_KpnS_SCNJ1-C,和vB_KpnM_SCNJ1-Y,针对CR-hvKP菌株SCNJ1,它们具有大小为43,428bp的双链DNA基因组,46,039bp,和50,360个基点,分别。系统发育分析表明,vB_KpnA_SCNJ1-Z属于Caudoviricetes类内的自拟病毒科,而vB_KpnS_SCNJ1-C和vB_KpnM_SCNJ1-Y是未分类的Caudoviricetes。噬菌体显示出狭窄的宿主范围,仅裂解50个测试的临床细菌菌株中的1个。一步生长曲线和稳定性结果表明,噬菌体表现出相对较短的潜伏期,具有宽pH(pH3-14)和热稳定性(20-60°C)。噬菌体对SCNJ1的生物膜形成有明显的抑制作用,体外抗菌活性强。在老鼠模型中,我们证明了单个噬菌体或噬菌体混合物的施用显着降低了肺中的细菌负荷,肝脏,和脾脏,并有效地从SCNJ1菌株的感染中拯救了小鼠,存活率为70-80%。这些发现表明这三种噬菌体作为替代疗法具有巨大的潜力,在体内和体外具有良好的稳定性和强大的抗菌活性,可用于治疗CR-hvKP感染。
The emergence of carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) has driven us to explore alternative treatments for the limitation of antimicrobial agents. Lytic phages are considered a promising alternative treatment for CR-hvKP infection. In this study, we reported three novel lytic phages, vB_KpnA_SCNJ1-Z, vB_KpnS_SCNJ1-C, and vB_KpnM_SCNJ1-Y, against a CR-hvKP strain SCNJ1, and they possess genomes of double-stranded DNA with a size of 43,428 bp, 46,039 bp, and 50,360 bp, respectively. Phylogenetic analysis demonstrated that vB_KpnA_SCNJ1-Z belongs to the family Autographiviridae within the class Caudoviricetes, while vB_KpnS_SCNJ1-C and vB_KpnM_SCNJ1-Y are unclassified Caudoviricetes. The phages showed a narrow host range only lysing 1 of 50 tested clinical bacterial strains. The one-step growth curves and stability results showed that the phages displayed relatively short latency periods, with broad pH (pH 3-14) and thermal stabilities (20-60°C). The phages showed significant inhibition of the biofilm formation by SCNJ1 and strong antibacterial activity in vitro. In the mouse model, we demonstrated that administration of a single phage or phage cocktail significantly reduced bacteria loads in the lung, liver, and spleen, and effectively rescued mice from the infection of the SCNJ1 strain, with a survival rate of 70-80%. These findings suggested the three phages have great potential as an alternative therapy with favorable stability and strong antibacterial activity both in vivo and in vitro for the treatment of CR-hvKP infection.